Mann, J;
Taylor, PW;
Dorgan, CR;
Johnson, PD;
Wilson, FX;
Vickers, R;
Dale, AG;
(2015)
The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic-industrial partnership.
MedChemComm
, 6
(8)
pp. 1420-1426.
10.1039/c5md00238a.
Preview |
Text
c5md00238a.pdf Download (1MB) | Preview |
Abstract
Academic drug discovery is playing an increasingly important role in the identification of new therapies for a wide range of diseases. There is no one model that guarantees success. We describe here a drug discovery story where chance, the ability to capitalise on chance, and the assembling of a range of expertise, have all played important roles in the discovery and subsequent development of an antibiotic chemotype based on the bis-benzimidazole scaffold, with potency against a number of current therapeutically challenging diseases. One compound in this class, SMT19969, has recently entered Phase 2 human clinical trials for the treatment of Clostridium difficile infections.
Archive Staff Only
 |
View Item |
